<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697045</url>
  </required_header>
  <id_info>
    <org_study_id>031-409-00036</org_study_id>
    <nct_id>NCT02697045</nct_id>
  </id_info>
  <brief_title>Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch</brief_title>
  <acronym>ARILAI</acronym>
  <official_title>Nautralsitic, Open-label, Single Arm Study Evaluating Effects of Aripiprazole LAI on Phychosocial&amp;Congitive Functioning, Patient Reported Acceptability of Treatment Regarding QoL, Subjective Well-being Under Neuroleptic Medication in Sch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abdi İbrahim Otsuka</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abdi İbrahim Otsuka</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nautralsitic, Open-label, Single Arm, Uncontrolled Study Evaluating the Effects of Long
      Acting Injectable (LAI) on Phychosocial Functioning Congitive Functioning and Patient
      Reported Acceptability of Treatment 'Reported Acceptability of Treatment' Regarding Quality
      of Life Subjective Well-being Under Neuroleptic Medication in Schizophrenia Patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective

        -  To evaluate the efficacy of aripiprazole long acting injectable form in Turkish patients
           with schizophrenia on psychosocial functioning, quality of life and patient reported
           acceptability of treatment. Secondary Objective(s)

        -  To evaluate the cognitive functioning of the patients

        -  To evaluate positive and negative symptoms of the Aripiprazole Long Acting Injectable
           (LAI),

        -  To evaluate adherence of Aripiprazole Long Acting Injectable (LAI) treatment,

        -  To evaluate tolerability of Aripiprazole Long Acting Injectable (LAI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2017</start_date>
  <completion_date type="Actual">March 31, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of aripiprazole long acting injectable form in Turkish patients with schizophrenia on psychosocial functioning assesed with psychosocial functioning scale</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of aripiprazole long acting injectable form in Turkish patients with schizophrenia quality of life assesed with Heinrich's quality of life scale</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of aripiprazole long acting injectable form in Turkish patients with schizophrenia patient reported acceptability of treatment assesed with Subjective Well Being Under Neuroleptic Treatment Scale</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the cognitive functioning of the patients assesed with PANNS Cognitive Items</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate positive and negative symptoms of the Aripiprazole Long Acting Injectable (LAI),</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate adherence of Aripiprazole Long Acting Injectable (LAI) treatment,</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate tolerability of Aripiprazole Long Acting Injectable (LAI)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>ARIPIPRAZOLE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ABILIFY MAINTENA 400 MG LAI Aripiprazole 400mg, IM, Once a month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole 400mg LAI</intervention_name>
    <description>Aripiprazole 400mg, IM, Once a month</description>
    <arm_group_label>ARIPIPRAZOLE</arm_group_label>
    <other_name>ABILIFY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               -  Participants 18-45 of years age fulfilling DSM-IV-TR diagnostic criteria of
                  schizophrenia,

               -  Disease history of ≤ 3 years (≤ 3 years after the emergence of first psychotic
                  symptoms),

               -  A history of symptom exacerbation or relapse when not receiving antipsychotics
                  therefore requiring maintenance antipsychotic treatment,

               -  Informed written consent,

               -  Not on any antipsychotic treatment at least for 3 months or requiring a switch in
                  treatment for any reason (lack of efficacy/ inadequate response to current
                  antipsychotic(s), intolerance, nonadherence), and with the potential to benefit
                  from extended treatment with an LAI formulation, in the investigator's opinion.

               -  Lack of efficacy is defined as subjects with a baseline total PANSS score ≥70 or
                  ≥2 items scoring ≥4 in the Positive or Negative Symptom Subscale

               -  Lack of tolerability is defined as the presence of clinically relevant side
                  effects with the previous antipsychotic medication.

               -  Being literate in order to be able to answer the self report scales.

          -  Exclusion Criteria:

               -  DSM-IV-TR diagnosis other than schizophrenia or experiencing acute depressive
                  symptoms in the past 30 days requiring ADT depending on the clinical decision of
                  the investigator.

               -  Antipsychotic resistant or refractory schizophrenia

               -  A history of failure to clozapine treatment or response to clozapine treatment
                  only.

               -  Significant risk of violent behavior or risk of self-harm

               -  Currently meets DSM-IV-TR criteria for alcohol and substance dependence

               -  Any clinically significant medical or neurological disorder

               -  Any medically significant abnormal laboratory test or ECG result at screening

               -  Pregnant, lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koksal Alptekin, Prof. Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz Eylul Universitesi Psiyatri Anabilim Dalı</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Çukurova Üniversitesi Tıp Fakültesi Balcalı Hastanesi Dahili Tıp Bilimleri Ruh Sağlığı ve Hastalıkları Anabilim Dalı, 01330 Balcalı/</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Atatürk Eğitim Araştırma Hastanesi Psikiyatri Kliniği, Üniversiteler Mahallesi Bilkent Caddesi No:1 ÇANKAYA / ANKARA</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Üniversitesi Tıp Fakültesi Ruh Sağlığı ve Hastalıkları Anabilim Dalı, Cebeci Yerleşkesi, Cebeci Ankara</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Üniversitesi Tıp Fakültesi Ruh Sağlığı ve Hastalıkları Anabilim Dalı, Hacettepe Mh. 06230 Ankara</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludağ Üniversitesi Tıp Fakültesi Hastanesi Psikiyatri ABD, Görükle Kampusu, 16059 Görükle/Nilüfer/Bursa</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erenköy Ruh ve Sinir Hastalıkları EAH Psikiyatri Polikliniği E servisi (Erkek Servisi) Eğitim Sorumlusu Başhekimlik Binası Uyku Laboratuarı 3. Kat Erenköy - Kadıköy - 34736 İstanbul</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erenköy Ruh ve Sinir Hastalıkları EAH Psikiyatri Polikliniği K servisi (Kadın Servisi) 2. Kat, Sinan Ercan Cad. No:29 Kazasker - Erenköy - Kadıköy - 34736 İstanbul</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>İstanbul Üniversitesi İstanbul Tıp Fakültesi Psikiyatri AD, Turgut Özal Caddesi No: 118 PK. 34093 Fatih/ İstanbul</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylül Üniversitesi Tıp Fakültesi Dahili Tıp Bilimleri Bölümü Ruh Sağlığı Ve Hastalıkları Anabilim Dalı Mithatpaşa Cad. No 1606 İnciraltı yerleşkesi 35340 Balçova / İzmir</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Üniversitesi Hastanesi Ruh Sağlığı ve Hastalıkları Anabilim Dalı, Kazımdirik, 35100 Bornova/İzmir</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kocaeli Üniversitesi Tıp Fakültesi Araştırma ve Uygulama Hastanesi Ruh Sağlığı ve Hastalıkları Anabilim Dalı, Eski İstanbul Yolu 10. Km. Umuttepe Yerleşkesi İzmit / Kocaeli</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sağlık Bilimleri Üniversitesi Konya Eğitim Araştırma Hastanesi, Meram, Konya</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manisa Ruh Sağlığı ve Hastalıkları Hastanesi Şehitler Mh. 814 Sk. No : 28 Merkez - Manisa</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mersin Üniversitesi Sağlık Araştırma ve Uygulama Merkezi Hastanesi Psikiyatri Anabilim Dalı Çiftlikköy Kampüsü 33343 Yenişehir-Mersin</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>19 Mayıs Üniversitesi Sağlık Uygulama ve Araştırma Merkezi Ruh Sağlığı ve Hastalıkları Anabilim Dalı Atakum / SAMSUN</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Functionality</keyword>
  <keyword>Long Acting Injectable</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Naturalistic</keyword>
  <keyword>Open-label</keyword>
  <keyword>Single Arm</keyword>
  <keyword>Uncontrolled Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

